Table 1 Partial important characteristics of patients in the without PDH group and in the with PDH group

Age (year)

49.91 ± 13.11

52.78 ± 13.59

0.153

Gender

0.755

 Female

85 (52.1%)

35 (55.6%)

 Male

78 (47.9%)

28 (44.4%)

Clinical subtype^a

0.650

 Nonfunctioning

107 (67.3%)

41 (66.1%)

 PRL secreting

7 (4.4%)

6 (9.7%)

 GH secreting

35 (22.0%)

12 (19.4%)

 ACTH secreting

7 (4.4%)

2 (3.2%)

 PRL-GH secreting

3 (1.9%)

1 (1.6%)

Preoperative hyponatremia^b

1.000

 No

151 (95.6%)

57 (95.0%)

 Yes

7 (4.4%)

3 (5.0%)

Hyponatremia on POD 1–2^c

0.098^*

 No

139 (90.8%)

48 (82.8%)

 Yes

14 (9.2%)

10 (17.2%)

Polyuria

0.609

 No

131 (80.4%)

48 (76.2%)

 Yes

32 (19.6%)

15 (23.8%)

Visual impairment^d

0.040^**

 No

83 (51.2%)

22 (34.9%)

 Yes

79 (48.8%)

41 (65.1%)

Hardy grade for suprasellar extension^b

0.038^**

 0

38 (24.2%)

15 (24.6%)

 A

41 (26.1%)

7 (11.5%)

 B

46 (29.3%)

16 (26.2%)

 C

28 (17.8%)

18 (29.5%)

 D

2 (1.3%)

2 (3.3%)

 E

2 (1.3%)

3 (4.9%)

Hardy grade for sellar invasion^b

0.264

 Noninvasive

119 (75.8%)

41 (67.2%)

 Invasive

38 (24.2%)

20 (32.8%)

Knosp grade^e

0.220

 Noninvasive

99 (62.7%)

32 (52.5%)

 Invasive

59 (37.3%)

29 (47.5%)

Tumor shape 1^f

0.067^*

 In sella

21 (16.2%)

9 (18.8%)

 Ellipsoid

51 (39.2%)

10 (20.8%)

 Hourglass sign

58 (44.6%)

29 (60.4%)

Tumor shape 2^f

0.452

 Not lobulated

118 (90.8%)

41 (85.4%)

 Lobulated

12 (9.2%)

7 (14.6%)

Log₁₀ (FSH) (IU/L)^g

0.90 ± 0.43

1.07 ± 0.46

0.021^**

FT3 (pmol/L)^h

4.47 ± 0.88

4.16 ± 0.56

0.039^**

WBC count (10⁹/L)^e

5.77 ± 1.58

5.13 ± 1.17

0.007^**

Monocyte percentage (%)^e

7.18 ± 1.70

7.76 ± 1.56

0.019^**

PT (s)ⁱ

11.30 ± 0.73

11.64 ± 0.80

0.002^**

INRⁱ

0.98 ± 0.06

1.01 ± 0.07

0.002^**

Total bilirubin (μmol/L)^j

13.12 ± 6.65

11.81 ± 4.65

0.307

Chlorine (mmol/L)^k

102.29 ± 2.80

102.90 ± 3.62

0.078^*